# EDGAR Filing Document

**Accession Number:** 0001557376
**File Stem:** 0001829126-26-002881
**Filing Date:** 2026-3
**Character Count:** 8960
**Document Hash:** 930e41c0d83bd639140eb046e30dd8dd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-26-002881.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0001829126-26-002881

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260331

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260331

**DATE AS OF CHANGE**: 20260331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zeo ScientifiX, Inc.
- **CENTRAL INDEX KEY:** 0001557376
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474180540
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55008
- **FILM NUMBER:** 26817160

**BUSINESS ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314
- **BUSINESS PHONE:** 888-963-7881

**MAIL ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Organicell Regenerative Medicine, Inc.
- **DATE OF NAME CHANGE:** 20180625

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biotech Products Services & Research, Inc.
- **DATE OF NAME CHANGE:** 20150917

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BESPOKE TRICYCLES INC
- **DATE OF NAME CHANGE:** 20120831

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **March 31, 2026**

**<u>ZEO SCIENTIFIX, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **000-55008** | **47-4180540** |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **3321 College Avenue, Suite 246<br> Davie, Florida** | **33314** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **<u>(888) 963-7881</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each Class** | **Trading Symbol** | **Name of each exchange on which registered** |
| None | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this "**Report**"), and unless otherwise indicated, the terms "**the Company**," "**ZEO**," "**we**," "**us**" and "**our**" refer to Zeo ScientifiX, Inc.

**Item 8.01 Other Events.**

On March 31, 2026, ZEO issued a press release announcing its role as the official educational partner for regenerative medicine with the American Academy of Anti-Aging Medicine (A4M) at the Longevity SpringFest 2026, where ZEO will lead a specialized, full-day Masterclass on regenerative and longevity medicine. The Masterclass will be held on April 9, 2026 in West Palm Beach, Florida.

A copy of the press release is included as **Exhibit 99.1** to this Report.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) *Exhibits* 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release, dated March 31, 2026](zeoscientifix_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: March 31, 2026 | **ZEO SCIENTIFIX, INC.** | **ZEO SCIENTIFIX, INC.** |
|  | By: | /s/ Ian T. Bothwell |
|  |  | Ian T. Bothwell<br> Chief Executive Officer and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**ZEO ScientifiX Solidifies Role as Official Regenerative Medicine Educational Partner for A4M at Longevity SpringFest 2026**

**ZEO Joins Publicly Traded Longevity Companies Like Niagen Bioscience (NASDAQ: NAGE) as Leaders in A4M's Educational Global Practitioner Network** 

**FORT LAUDERDALE, Fla. – March 31, 2026** – ZEO ScientifiX, Inc. (OTCQB: ZEOX) ("ZEO" or the "Company"), a clinical-stage biotechnology company, today announced its role as the **official educational partner for regenerative medicine** with the <u>American Academy of Anti-Aging Medicine</u> (A4M) at the Longevity SpringFest 2026.

Modeled after A4M's prestigious Professional Medical Education (PME) series, ZEO will serve as the "official arm of education" for regenerative medicine. The Company will lead a specialized, full-day Masterclass on April 9, 2026, in West Palm Beach, providing evidence-based training to attending physicians. This collaboration allows ZEO direct access to A4M's network of 26,000 physicians and health care practitioners representing over 120 nations.

This strategic partnership places ZEO alongside other industry-leading public companies that are partners within the A4M educational-network, including NASDAQ-listed <u>Niagen Bioscience (NAGE)</u> and InBody (KRX: 041830), emphasizing the Company's position in the overall $29.9 billion longevity therapy market (The Business Research Company, 2026).

"We are incredibly excited to bring this level of specialized physician education to West Palm Beach," said **Dr. George C. Shapiro MD, Chief Medical Officer of ZEO**. "By modeling this Masterclass after A4M's renowned Professional Medical Education series, ZEO is helping set a new standard for how regenerative medicine is taught and implemented. As Chair of the educational session, my goal is to ensure clinicians leave with a rigorous, evidence-based framework to safely and effectively lead the next wave of regenerative and longevity medicine."

**The Regenerative & Longevity Medicine Masterclass**

Designed for advanced practitioners, the program will cover:

● **Scientific Foundations:** Differentiating cellular vs. acellular biologics and manufacturing quality standards.

● **Clinical Integration:** Real-world applications for musculoskeletal, orthopedic, and oncology-adjacent care.

● **Regulatory Compliance:** Navigating federal and Florida-specific biologic legislation.

**About ZEO ScientifiX, Inc.** ZEO ScientifiX, Inc. (OTCQB: ZEOX) is an SEC-reporting, clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. Operating out of Nova Southeastern University's $100 Million Center of Collaborative Research, the Company translates emerging science into scalable clinical solutions. For more information, visit <u>https://zeoscientifix.com</u>.

**Forward-Looking Statements** Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. ZEO has no intention and specifically disclaims any duty to update the information in this press release.

**Media Contact:**

ZEO ScientifiX, Inc.

Karlista Maroney

Director of Growth Strategy

IR@zeoscientifix.com